Lexeo Therapeutics, Inc.
LXEO
$5.09
-$0.41-7.46%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 3.46% | -3.14% | 22.30% | 20.07% | -25.97% |
| Total Depreciation and Amortization | 1.49% | 1.51% | 3.92% | 1.80% | -3.84% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.44% | -0.37% | 1,051.23% | -107.68% | 6.46% |
| Change in Net Operating Assets | -75.36% | 80.82% | -832.51% | -119.93% | 205.04% |
| Cash from Operations | -5.30% | 32.04% | -8.55% | -25.34% | 23.34% |
| Capital Expenditure | -- | 100.00% | -167.59% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 127.04% | -388.07% | 190.36% | -350.42% | 116.67% |
| Cash from Investing | 127.00% | -390.45% | 189.37% | -351.12% | 116.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 28.40% | -103.61% | 31.97% | 23.27% | -37.07% |
| Issuance of Common Stock | -98.31% | 113,806.67% | -99.83% | 46,958.24% | 639.13% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 99.75% | -- | 100.00% | -- | -- |
| Cash from Financing | -98.29% | 276,384.62% | -99.93% | 663,172.73% | 111.34% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -60.15% | 298.91% | -16.00% | 207.57% | 95.00% |